BCM
PDLI

Bridgeway Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Bridgeway Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-971,800
Closed -$2.1M – 1453
2019
Q3 		$2.1M Hold
971,800
– – 0.03% 490
2019
Q2 		$3.05M Hold
971,800
– – 0.04% 368
2019
Q1 		$3.62M Hold
971,800
– – 0.05% 321
2018
Q4 		$2.82M Hold
971,800
– – 0.04% 368
2018
Q3 		$2.56M Sell
971,800
-100,000
-9% -$245K 0.02% 550
2018
Q2 		$2.51M Buy
1,071,800
+220,800
+26% +$616K 0.03% 545
2018
Q1 		$2.5M Hold
851,000
– – 0.03% 509
2017
Q4 		$2.33M Buy
851,000
+801,000
+1,602% +$2.46M 0.03% 543
2017
Q3 		$170K Hold
50,000
– – ﹤0.01% 1303
2017
Q2 		$124K Hold
50,000
– – ﹤0.01% 1345
2017
Q1 		$114K Hold
50,000
– – ﹤0.01% 1327
2016
Q4 		$106K Sell
50,000
-428,400
-90% -$1.2M ﹤0.01% 1357
2016
Q3 		$1.6M Hold
478,400
– – 0.02% 614
2016
Q2 		$1.5M Hold
478,400
– – 0.02% 633
2016
Q1 		$1.59M Hold
478,400
– – 0.03% 591
2015
Q4 		$1.69M Buy
478,400
+90,300
+23% +$378K 0.03% 540
2015
Q3 		$1.95M Sell
388,100
-6,300
-2% -$36.1K 0.04% 495
2015
Q2 		$2.54M Sell
394,400
-2,800
-0.7% -$18.8K 0.05% 429
2015
Q1 		$2.79M Buy
397,200
+54,700
+16% +$396K 0.06% 400
2014
Q4 		$2.64M Buy
342,500
+27,320
+9% +$216K 0.06% 415
2014
Q3 		$2.35M Buy
315,180
+7,480
+2% +$69.4K 0.06% 422
2014
Q2 		$2.98M Sell
307,700
-6,700
-2% -$59.7K 0.08% 366
2014
Q1 		$2.61M Sell
314,400
-5,900
-2% -$50.6K 0.07% 395
2013
Q4 		$2.7M Buy
320,300
+22,200
+7% +$187K 0.08% 349
2013
Q3 		$2.38M Buy
298,100
+39,650
+15% +$319K 0.08% 343
2013
Q2 		$2M Buy
+258,450
New +$2.02M 0.08% 333

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bridgeway Capital Management's PDLI Position: Q4 2019 in Review

Bridgeway Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 971,800 shares — an estimated $2.1M sold.

Bridgeway Capital Management first reported a position in PDLI in Q2 2013 and held it in 26 quarters. The position peaked at $3.62M in Q1 2019. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

  • Bridgeway Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • Bridgeway Capital Management sold 971,800 PDL BioPharma, Inc. shares in Q4 2019, an estimated $2.1M.
  • Bridgeway Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 26 quarters.
  • Bridgeway Capital Management's PDL BioPharma, Inc. position peaked at $3.62M in Q1 2019.
  • 150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on Bridgeway Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.